Skip to main content
XFOR
NASDAQ Life Sciences

FDA Agrees to Cut 4WARD Trial Size to 126 Patients, Clearing Path to Faster Data

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$4.124
Mkt Cap
$400.553M
52W Low
$2.8
52W High
$4.83
52W Position info
47% above low
Off High info
15% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

XFOR sits 47% above its 52-week low of $2.8 on light trading volume (0.2× avg).

Summary

X4 Pharmaceuticals announced the FDA agreed to reduce the 4WARD Phase 3 trial size from 176 to 126 patients while maintaining adequate statistical power, with enrollment expected to complete by year-end 2026 and topline data in H1 2028.


Key Events · Product Development and Regulatory · XFOR

  • FDA Agrees to Smaller 4WARD Trial

    FDA agreed to reduce the 4WARD Phase 3 trial sample size from 176 to 126 participants while maintaining adequate power for the co-primary endpoints of annualized infection rate reduction and positive ANC response.

  • Safety Database Accepted for sNDA

    FDA indicated the proposed safety database would be acceptable to support a potential supplemental new drug application (sNDA) for mavorixafor in chronic neutropenia.

  • Enrollment and Data Timeline

    Company expects to complete 4WARD enrollment by year-end 2026 and report topline data in the first half of 2028.

  • Regulatory Risk Remains

    FDA feedback from the Type C meeting is not binding; the agency could take a different position during sNDA review, and the reduced sample size could still fail to show statistical significance.


Analysis · XFOR · Life Sciences

The FDA's agreement to reduce the 4WARD Phase 3 trial from 176 to 126 participants is a meaningful regulatory win. It preserves statistical power for the co-primary endpoints while cutting enrollment burden by nearly 30%, which should accelerate completion to year-end 2026 and pull topline data into H1 2028. The FDA also accepted the proposed safety database for a potential sNDA, de-risking the path to a supplemental approval for mavorixafor in chronic neutropenia. This is not a binding commitment — the FDA could still take a different position at review — but it materially improves the probability of a successful, timely filing.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3715 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, XFOR was trading at $4.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $400.6M. The 52-week trading range was $2.80 to $4.83. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XFOR - Latest Insights

XFOR
Nov 04, 2026, 4:15 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.24
Real-time Price: $3.12 info
Change: -$0.120 (-4%) info
Market Cap: $318.594M info
XFOR
Nov 04, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.24
Real-time Price: $3.12 info
Change: -$0.120 (-4%) info
Market Cap: $318.594M info
XFOR
Oct 29, 2026, 9:59 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.44
Real-time Price: $3.12 info
Change: -$0.320 (-9%) info
Market Cap: $318.594M info
XFOR
Oct 08, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.81
Real-time Price: $3.12 info
Change: +$0.3099 (+11%) info
Market Cap: $318.594M info
XFOR
Sep 08, 2026, 5:36 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.60
Real-time Price: $3.12 info
Change: -$0.480 (-13%) info
Market Cap: $318.594M info